ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » North Carolina » Rheumatology

Top Rheumatology Prescribers in North Carolina

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
BOB WODECKI MD

Rheumatology

11,375

$1.02M

941
537 are 65+

4%
patients receiving schedule two controlled substances

Avg: 4%

29%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 23%

$90
Average prescription price

Avg: $147

PAUL FERRELL MD

Rheumatology

10,537

$496K

477
402 are 65+

4%
patients receiving schedule two controlled substances

Avg: 4%

18%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 23%

$47
Average prescription price

Avg: $147

KRISTIN GOWIN M.D.

Rheumatology

8,431

$1.66M

573
338 are 65+

4%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

31%
prescriptions for brand name drugs

Avg: 23%

$197
Average prescription price

Avg: $147

DAYTON PAYNE M.D.

Rheumatology

8,393

$1.34M

634
366 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

17%
patients receiving schedule three controlled substances

Avg: 9%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 23%

$160
Average prescription price

Avg: $147

WILLIAM BYRD MD

Rheumatology

7,653

$430K

429
329 are 65+

15%
patients receiving schedule two controlled substances

Avg: 4%

6%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 23%

$56
Average prescription price

Avg: $147

NAJEEB GHAUSSY MD

Rheumatology

7,529

$794K

547
292 are 65+

7%
patients receiving schedule two controlled substances

Avg: 4%

33%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 23%

$106
Average prescription price

Avg: $147

JEFFREY ALLOWAY MD

Rheumatology

7,057

$1.08M

691
432 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

20%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 23%

$153
Average prescription price

Avg: $147

DUNCAN FAGUNDUS MD

Rheumatology

6,466

$803K

586
385 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

17%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 23%

$124
Average prescription price

Avg: $147

GARLAND MOELLER MD

Rheumatology

6,426

$918K

348
269 are 65+

4%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

35%
prescriptions for brand name drugs

Avg: 23%

$143
Average prescription price

Avg: $147

NICHOLAS PATRONE MD

Rheumatology

5,952

$530K

613
401 are 65+

12%
patients receiving schedule two controlled substances

Avg: 4%

23%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 23%

$89
Average prescription price

Avg: $147

ELLISON SMITH M.D.

Rheumatology

5,846

$1.12M

434
306 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

4%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 23%

$191
Average prescription price

Avg: $147

JILL VARGO M.D.

Rheumatology

5,807

$1.04M

499
354 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

4%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 23%

$179
Average prescription price

Avg: $147

DOUGLAS METCALF M.D.

Rheumatology

5,496

$1.04M

603
448 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 23%

$189
Average prescription price

Avg: $147

JAMES PERRUQUET M.D.

Rheumatology

5,308

$596K

424
247 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

17%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 23%

$112
Average prescription price

Avg: $147

FREDERICK TALIP M.D.

Rheumatology

5,285

$720K

521
303 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

8%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 23%

$136
Average prescription price

Avg: $147

GEORGE KERNODLE M.D.

Rheumatology

5,204

$468K

552
460 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

9%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 23%

$90
Average prescription price

Avg: $147

AJAY AJMANI MD

Rheumatology

5,095

$1.1M

247
127 are 65+

13%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

29%
prescriptions for brand name drugs

Avg: 23%

$217
Average prescription price

Avg: $147

STEVEN MENDELSOHN M.D.

Rheumatology

4,891

$638K

439
275 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

4%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 23%

$130
Average prescription price

Avg: $147

ANTHONY ANDERSON MD

Rheumatology

4,278

$492K

415
326 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

26%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 23%

$115
Average prescription price

Avg: $147

JOHN WINFIELD M.D.

Rheumatology

4,162

$542K

305
141 are 65+

14%
patients receiving schedule two controlled substances

Avg: 4%

27%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

28%
prescriptions for brand name drugs

Avg: 23%

$130
Average prescription price

Avg: $147

JULIO BRAVO M.D.

Rheumatology

4,065

$711K

434
290 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

28%
prescriptions for brand name drugs

Avg: 23%

$175
Average prescription price

Avg: $147

RANDAL WHITE M.D.

Rheumatology

3,961

$801K

449
324 are 65+

10%
patients receiving schedule two controlled substances

Avg: 4%

22%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 23%

$202
Average prescription price

Avg: $147

ROBERT GAY MD

Rheumatology

3,956

$984K

383
273 are 65+

9%
patients receiving schedule two controlled substances

Avg: 4%

10%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

30%
prescriptions for brand name drugs

Avg: 23%

$249
Average prescription price

Avg: $147

ROBERT KIPNIS MD

Rheumatology

3,951

$446K

394
298 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

13%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 23%

$113
Average prescription price

Avg: $147

SHAILI DEVESHWAR MD

Rheumatology

3,927

$485K

446
304 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

10%
patients receiving schedule three controlled substances

Avg: 9%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 23%

$123
Average prescription price

Avg: $147

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank